FDA Approves Nivolumab with Chemotherapy for Previously Untreated Hodgkin Lymphoma By Ogkologos - April 1, 2026 214 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the Study CA209-8UT (SWOG 1826) Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Relacorilant Annual Multicancer Early Detection Test Not Associated with a Lower Incidence Rate of Stage III or IV Cancer After Three Screening Rounds and 12... ESMO welcomes the adoption of European Parliament Report on Europe’s Beating Cancer Plan in the Committee on Public Health (SANT), calls for further EU... MOST POPULAR Daraxonrasib Shows Antitumour Activity in Patients with Previously Treated Metastatic RAS-mutated... September 10, 2026 Silence Speaks Volumes June 16, 2020 Liquid Biopsy May Predict Risk of Breast Cancer Returning Years Later August 15, 2018 Prevention and Early Detection of Gastrointestinal Cancers Take on New Importance... June 27, 2024 Load more HOT NEWS How We’re Working to Build a Cancer Survivorship Community: Survivors’ Perspectives A Lack of Resistance Gene Alterations in Baseline ctDNA Associated with... Long-Term Outcomes Suggest a Sustained Clinical Benefit to Metastasis-Directed Treatment Over... FDA Approves Neoadjuvant/Adjuvant Durvalumab for Patients with Resectable NSCLC
